News Focus
News Focus
Followers 843
Posts 122874
Boards Moderated 9
Alias Born 09/05/2002

Re: bladerunner1717 post# 2817

Sunday, 06/14/2009 10:30:26 PM

Sunday, June 14, 2009 10:30:26 PM

Post# of 3757
Re: Cash burn

Do you expect any of the milestones from GSK to offset IDIX's need for cash in the near future?

Not to a significant degree. I expect IDIX to raise cash opportunistically during 2H09—see the bottom paragraph of #msg-37454545.

…they seem to be a bit of a cash-burn machine.

I suspect that you think this because your views have been colored by the various virtual biotech you follow. Those companies operate on a shoestring and try to in-license compounds cheaply—often the compounds that no one else wants.

IDIX is the polar opposite of a virtual biotech company insofar as it discovers its compounds in-house. IDX184, IDX375, IDX136, IDX316, and IDX899 (the drug recently partnered with GSK) were all discovered internally. I don’t consider IDIX’s cash burn unduly high for a company that maintains such a productive drug-discovery team.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y